BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25248114)

  • 1. Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma.
    Rauh-Hain JA; Hinchcliff EM; Oduyebo T; Worley MJ; Andrade CA; Schorge JO; George S; Muto MG; del Carmen MG
    Int J Gynecol Cancer; 2014 Oct; 24(8):1434-40. PubMed ID: 25248114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine leiomyosarcoma: an updated series.
    Rauh-Hain JA; Oduyebo T; Diver EJ; Guseh SH; George S; Muto MG; del Carmen MG
    Int J Gynecol Cancer; 2013 Jul; 23(6):1036-43. PubMed ID: 23714705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
    Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
    Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study.
    Bizzarri N; Ghirardi V; Di Fiore GLM; De Iaco P; Gadducci A; Casarin J; Perrone AM; Pasciuto T; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2019 Sep; 29(7):1134-1140. PubMed ID: 31420411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience.
    Mahdavi A; Monk BJ; Ragazzo J; Hunter MI; Lentz SE; Vasilev SA; Tewari KS
    Int J Gynecol Cancer; 2009 Aug; 19(6):1080-4. PubMed ID: 19820372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?
    Worhunsky DJ; Gupta M; Gholami S; Tran TB; Ganjoo KN; van de Rijn M; Visser BC; Norton JA; Poultsides GA
    J Surg Oncol; 2015 Jun; 111(7):808-12. PubMed ID: 25920434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
    Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
    BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine leiomyosarcoma: analysis of treatment failures and survival.
    Gadducci A; Landoni F; Sartori E; Zola P; Maggino T; Lissoni A; Bazzurini L; Arisio R; Romagnolo C; Cristofani R
    Gynecol Oncol; 1996 Jul; 62(1):25-32. PubMed ID: 8690287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic pattern of uterine leiomyosarcoma: retrospective analysis of the predictors and outcome in 113 patients.
    Tirumani SH; Deaver P; Shinagare AB; Tirumani H; Hornick JL; George S; Ramaiya NH
    J Gynecol Oncol; 2014 Oct; 25(4):306-12. PubMed ID: 25142630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma.
    Leitao MM; Brennan MF; Hensley M; Sonoda Y; Hummer A; Bhaskaran D; Venkatraman E; Alektiar K; Barakat RR
    Gynecol Oncol; 2002 Dec; 87(3):287-94. PubMed ID: 12468327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
    Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
    Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma.
    Schwameis R; Grimm C; Petru E; Natter C; Staudigl C; Lamm W; Koelbl H; Krainer M; Brodowicz T; Reinthaller A; Polterauer S
    PLoS One; 2015; 10(8):e0133838. PubMed ID: 26248232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncological outcomes of unexpected uterine leiomyosarcoma: A single-center retrospective analysis of 5528 consecutive hysterectomies.
    Casarin J; Ghezzi F; Lembo A; Artuso V; Schivardi G; Galati EF; Ambrosoli AL; Bogani G; Multinu F; Cromi A
    J Surg Oncol; 2024 Mar; 129(3):517-522. PubMed ID: 37974522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study.
    Garg G; Shah JP; Liu JR; Bryant CS; Kumar S; Munkarah A; Morris RT
    Int J Gynecol Cancer; 2010 Oct; 20(7):1201-6. PubMed ID: 20940535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
    Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
    Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
    George S; Barysauskas C; Serrano C; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Demetri GD; Muto MG
    Cancer; 2014 Oct; 120(20):3154-8. PubMed ID: 24923260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma.
    Giuntoli RL; Garrett-Mayer E; Bristow RE; Gostout BS
    Gynecol Oncol; 2007 Jul; 106(1):82-8. PubMed ID: 17434579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.